Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 501–600 of 1,000
Aoki, M., Iwasa, S., & Boku, N. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01164-x · Cited by 36
Kato, T., Okada, R., Furusawa, A., Inagaki, F. F., Wakiyama, H., Furumoto, H., Okuyama, S., Fukushima, H., Choyke, P. L., & Kobayashi, H. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0470 · Cited by 39
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 40
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
Witt, R. G., Erstad, D. J., & Wargo, J. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083052 · Cited by 39
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Advances in targeted therapy and immunotherapy for melanoma (Review)
Qin, Z., & Zheng, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12115 · Cited by 37
Checkpoint inhibitor-associated immune arthritis
Arnaud, L., Lebrun‐Vignes, B., & Salem, J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213470 · Cited by 35
Chan, W. Y., Lee, J., Stewart, A., Diefenbach, R. J., Gonzalez, M., Menzies, A. M., Blank, C. U., Scolyer, R. A., Long, G. V., & Rizos, H. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03153-1 · Cited by 35
“The true rate of recurrence is likely greater as 15–20% of melanoma patients develop disease recurrence prior to initiation of adjuvant therapy, indicating the presence of micrometa-static disease at time of surgery [4].”
BackgroundSelf-citationElkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Feld, E., & Mitchell, T. C. (2018) · Immunotherapy · doi:10.2217/imt-2017-0143 · Cited by 39
Adjuvant Ipilimumab in High-Risk Uveal Melanoma
Fountain, E., Bassett, R. L., Cain, S., Posada, L., Gombos, D. S., Hwu, P., Bedikian, A. Y., & Patel, S. P. (2019) · Cancers · doi:10.3390/cancers11020152 · Cited by 35
The extent of surgery for stage III melanoma: how much is appropriate?
Franke, V., & van Akkooi, A. C. J. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30099-3 · Cited by 36
Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis
Nelson, D. W., Fischer, T. D., Graff‐Baker, A. N., Dehal, A. N., Stern, S. L., Bilchik, A. J., & Faries, M. B. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07487-5 · Cited by 34
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot
Janjigian, Y. Y., Wolchok, J. D., & Ariyan, C. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.013 · Cited by 35
Ferrari, A., Almaraz, R. L., Réguerre, Y., Česen, M., Bergamaschi, L., Indini, A., Schneider, D. T., Godzinski, J. K., Bień, E., Stachowicz‐Stencel, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28992 · Cited by 39
Evolving Treatment Approaches to Mucosal Melanoma
Zhang, S., Zhang, J., Guo, J., Si, L., & Bai, X. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01225-z · Cited by 34
Schumann, K., Mauch, C., Klespe, K., Loquai, C., Nikfarjam, U., Schlaak, M. S., Akcetin, S. L., Kölblinger, P., Hoellwerth, M., Meißner, M., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18779 · Cited by 38
Novel Immunotherapies for T Cell Lymphoma and Leukemia
Ghione, P., Moskowitz, A. J., Paola, N. D., Horwitz, S. M., & Ruella, M. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0480-8 · Cited by 37
Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45357-1 · Cited by 33
“…antibody), pembrolizumab and nivolumab (both monoclonal antibodies against programmed death 1 [PD-1]), and combination of BRAF and MEK inhibitors for patients whose tumors harbor a BRAF mutation 1,4 – 12 , leading to US Food and Drug Administration approvals.”
Immune checkpoint inhibitors and acute kidney injury
Zhou, P., Gao, Y., Kong, Z., Wang, J., Si, S., Han, W., Li, J., Lv, Z., & Wang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353339 · Cited by 40
“As examples, the common dermatitis usually develops within 4 weeks (44, 66, 67) and colitis within 6 weeks after ICIs treatment (43).”
BackgroundYang, W., Li, S., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000015731 · Cited by 36
“mg every 3 week) plus chemotherapy Weber et al [27]”
The increasing use of shave biopsy for diagnosing invasive melanoma in Australia
de Menezes, S. L., Kelly, J. W., Wolfe, R. S., Farrugia, H., & Mar, V. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50289 · Cited by 33
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 37
“First, while BRAF V600 mutations predict response to targeted therapy, patients are also eligible to receive ICI in either the adjuvant [92,93] or metastatic [94–98] setting regardless of BRAF mutation status.”
BackgroundDimitriou, F., Staeger, R., Ak, M., Maissen, M., Kudura, K., Barysch, M. J., Levesque, M. P., Cheng, P. F., Dummer, R., & Mangana, J. (2021) · Cancers · doi:10.3390/cancers13122931 · Cited by 35
“Besides, nivolumab was initially tested at 3 mg/kg 2-weekly in the CheckMate238 trial [4] and nivolumab/ipilimumab are administered at a dose of 1 and 3 mg/kg 3-weekly at the induction phase.”
MethodCutaneous toxicities of new treatments for melanoma
Boada, A., Carrera, C., Segura, S., Collgros, H., Pasquali, P., Bodet, D., Puig, S., & Malvehy, J. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1891-7 · Cited by 34
Adjuvant therapy for stage II melanoma: the need for further studies
Lee, R. J., Mandalà, M., Long, G. V., Eggermont, A. M. M., van Akkooi, A. C. J., Sandhu, S. K., Garbe, C., & Lorigan, P. C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.003 · Cited by 33
Self-citationDiagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 38
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 42
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations
Valdez-Salazar, F., Rio, L. A. J.-D., Padilla‐Gutiérrez, J. R., Valle, Y., Muñóz-Valle, J. F., & Valdés‐Alvarado, E. (2024) · Biomedicines · doi:10.3390/biomedicines12081851 · Cited by 41
“Although associated with significant immune-related adverse events, ipilimumab has shown durable responses and improved survival in some patients with advanced melanoma [87,197].”
BackgroundZhang, Z., Langenbach, M., Sagar, S., Fetsch, V., Stritzker, J., Severa, E., Meng, K., Winkler, F., Rana, N., Zoldan, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02027-0 · Cited by 38
Self-citationTumour budding in rectal cancer. A comprehensive review
Lino-Silva, L. S., Salcedo‐Hernández, R. A., & Gamboa‐Domínguez, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.77043 · Cited by 39
McKean, M. A., & Amaria, R. N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.011 · Cited by 34
Heudel, P., Chabaud, S., Pérol, D., Fléchon, A., Fayette, J., Combemale, P., Trédan, O., Desseigne, F., de la Fouchardière, C., Boyle, H., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100044 · Cited by 32
Wölffer, M., Battke, F., Schulze, M., Feldhahn, M., Flatz, L., Martus, P., & Forschner, A. (2022) · Cancers · doi:10.3390/cancers14020302 · Cited by 38
“However, ICI might be associated with immune-related adverse events (IRAE), up to 59% in case of combined ICI [2].”
BackgroundLarkin, J., Weber, J. S., Vecchio, M. D., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J., Chiarion‐Sileni, V., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.041 · Cited by 39
Self-citationda Silva, G. B., Manica, D., da Silva, A. P., Marafon, F., Moreno, M., & Bagatini, M. D. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110427 · Cited by 35
Bloemendal, M., van Willigen, W. W., Bol, K. F., Boers‐Sonderen, M. J., Bonenkamp, J. J., Werner, J. E. M., Aarntzen, E. H. J. G., Koornstra, R. H. T., de Groot, J. W. B., de Vries, I. J. M., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07274-2 · Cited by 34
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., Long, G. V., & da Silva, I. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030147 · Cited by 36
Self-citationHelgadóttir, H., Ny, L., Ullenhag, G. J., Falkenius, J., Mikiver, R., Bagge, R. O., & Isaksson, K. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad081 · Cited by 32
Fiorentino, V., Pizzimenti, C., Franchina, M., Pepe, L. R., Russotto, F., Tralongo, P., Micali, M. G., Militi, G. B., & Lentini, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010676 · Cited by 35
Helgadóttir, H., Matikas, A., Fernebro, J., Frödin, J., Ekman, S., & Rodriguez‐Wallberg, K. A. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114010 · Cited by 34
Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma Progression
Wu, C. Y.-J., Chen, Y., Lin, Y.-J., Wei, K., Chang, K., Feng, L.-Y., Chen, K., Li, G., Ren, A. L., Nitta, R. T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0018 · Cited by 32
Avelumab: a new standard for treating metastatic Merkel cell carcinoma
Baker, M., Cordes, L. M., & Brownell, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1445528 · Cited by 37
Bensimon, A. G., Zhou, Z., Jenkins, M. D., Song, Y., Gao, W., Signorovitch, J., Krepler, C., Liu, F. X., Wang, J., & Aguiar‐Ibáñez, R. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1609485 · Cited by 31
Li, M., Liu, D., Lee, D., Kapoor, S., Gibson-Corley, K. N., Quinn, T. P., Sagastume, E. A., Mott, S. L., Walsh, S. A., Acevedo, M. R., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00512 · Cited by 35
Weber, J., Glutsch, V., Geissinger, E., Haug, L., Lock, J. F., Schneider, F., Kneitz, H., Goebeler, M., Schilling, B., & Gesierich, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18739 · Cited by 33
Self-citationPredictive biomarkers of response to immune checkpoint inhibitors in melanoma
Nebhan, C. A., & Johnson, D. B. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1724539 · Cited by 32
Checkpoint Inhibitors and Hepatotoxicity
Malnick, S. D. H., Abdullah, A., & Neuman, M. G. (2021) · Biomedicines · doi:10.3390/biomedicines9020101 · Cited by 32
Adjuvant immunotherapy for melanoma
Thomas, D. C., & Bello, D. M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26329 · Cited by 37
“20‐22 The benefit of anti‐PD‐1 monoclonal antibodies as an adjuvant therapy was first demonstrated in the Checkmate 238 randomized clinical trial comparing nivolumab or ipilimumab 10mg/kg.(51) This trial enrolled 906 patients with completely resected high‐risk stage IIIB, IIIC, or IV melanoma.”
BackgroundA review of the AJCC melanoma staging system in the TNM classification (eighth edition)
Ogata, D., Namikawa, K., Takahashi, A., & Yamazaki, N. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab022 · Cited by 34
Self-citationSEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem, M., Manzano, J. L., Márquez‐Rodas, I., Mujika, K., Muñoz‐Couselo, E., Pérez-Ruiz, E., de la Cruz‐Merino, L., Espinosa, E., González‐Cao, M., & Berrocal, A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02539-9 · Cited by 34
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W. J. M., Ch’ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.012 · Cited by 33
Self-citationThompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 32
“The first adjuvant ICI trials in patients with resected melanoma at high risk of recurrence have reported improvements in relapsefree survival [18, 19] and adjuvant checkpoint blockade is now being tested in other cancers.”
Zhang, Y., Liu, B., Kotenko, S. V., & Li, W. (2022) · Medicine · doi:10.1097/md.0000000000029536 · Cited by 31
Huo, G., Liu, W., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10605-y · Cited by 31
Mandalà, M., Merelli, B., Indriolo, A., & Tondini, C. A. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.019 · Cited by 31
Takayasu, Y., Kubo, N., Shino, M., Nikkuni, O., Ida, S., Musha, A., Takahashi, K., Hirato, J., Shirai, K., Saitoh, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2614 · Cited by 32
Miao, J., Sise, M. E., & Herrmann, S. M. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.1017921 · Cited by 34
The relationship between autophagy and PD-L1 and their role in antitumor therapy
Cui, Y., Shi, J., Cui, Y., Zhu, Z., & Zhu, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093558 · Cited by 36
“The high expression of PD-L1 in different tumors is closely related to poor survival rates, prognoses, and treatment effects (49, 50).”
BackgroundAdjuvant immunotherapy for melanoma patients: progress and opportunities
Sussman, T. A., & Ott, P. A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102962 · Cited by 32
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
Sinicrope, F. A., Ou, F., Arnold, D., Peters, W. R., Behrens, R. J., Lieu, C. H., Matin, K., Cohen, D. J., Potter, S. L. P., Nixon, A. B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2507874 · Cited by 43
“ATOMIC evaluated 12 months of adjuvant atezolizumab based on pivotal melanoma trial data showing durable survival benefit with one year of checkpoint inhibition, 18 and current regulatory approvals for adjuvant immune checkpoint inhibitor therapy specify a treatment duration of one year.”
Huang, Y., Fan, H., Li, N., & Du, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2104 · Cited by 32
Immune checkpoint inhibitors in malignancy
Ardolino, L., & Joshua, A. M. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.012 · Cited by 31
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Toripalimab for the treatment of melanoma
Tang, B., Chi, Z., & Guo, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762561 · Cited by 30
“have also been tested as neoadjuvant therapy [9,10,31].”
MethodArora, P. C., Talamo, L., Dillon, P. M., Gentzler, R. D., Millard, T. A., Salerno, M., Slingluff, C. L., & Gaughan, E. M. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-00076-6 · Cited by 36
“potential benefit and toxicity from treatment [1, 2].”
Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)
Gao, L., & Chen, Y. (2021) · Biomedical Reports · doi:10.3892/br.2021.1460 · Cited by 32
Atkinson, V. G., Robert, C., Grob, J., Gogas, H. J., Dutriaux, C., Демидов, Л. В., Gupta, A. K., Menzies, A. M., Ryll, B., Miranda, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.015 · Cited by 30
Self-citationToxicities associated with immune checkpoint inhibitors: a systematic study
Kong, X., Chen, L., Su, Z., Sullivan, R. J., Blum, S. M., Qi, Z., Liu, Y., Huo, Y., Fang, Y., Zhang, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000368 · Cited by 32
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Ascierto, P. A., Vecchio, M. D., Merelli, B., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Gaudy‐Marqueste, C., Pigozzo, J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504966 · Cited by 29
Self-citationPediatric Melanoma and Atypical Melanocytic Neoplasms
Kumar, R. S., Messina, J. L., Reed, D. R., Navid, F., & Sondak, V. K. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_15 · Cited by 32
Grob, J., Garbe, C., Ascierto, P. A., Larkin, J., Dummer, R., & Schadendorf, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30596-5 · Cited by 30
Self-citationYuen, K. C. J., POPOVIC, V. M., & Trainer, P. J. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.010 · Cited by 30
Novel Delivery Systems for Checkpoint Inhibitors
Lamichhane, P., Deshmukh, R. R., Brown, J. K., Jakubski, S., Parajuli, P., Nolan, T. A., Raja, D. S., Badawy, M., Yoon, T., Zmiyiwsky, M., et al. (2019) · Medicines · doi:10.3390/medicines6030074 · Cited by 32
“For example, 46% grade III and IV adverse events and 42% treatment discontinuation, associated with adverse events, have been reported for Ipilimumab (anti-CTLA-4; Bristol-Myers Squibb) treatment [20].”
BackgroundTNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma
Roszik, J., Markovits, E., Dobosz, P., Layani, A., Slabodnik-Kaner, K., Baruch, E. N., Ben‐Betzalel, G., Grimm, E. A., Berger, R., Sidi, Y., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02382-0 · Cited by 30
Management of V600E and V600K BRAF-Mutant Melanoma
Haugh, A. M., & Johnson, D. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0680-z · Cited by 33
Longo, C., Pampena, R., Lallas, A., Kyrgidis, Α., Stratigos, A., Peris, K., Garbe, C., & Pellacani, G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16074 · Cited by 30
Keung, E. Z.-Y., & Gershenwald, J. E. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa012 · Cited by 41
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
Patrinely, J. R., Dewan, A. K., & Johnson, D. B. (2020) · BioDrugs · doi:10.1007/s40259-020-00428-9 · Cited by 31
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression
Bay, M. L., Unterrainer, N., Stagaard, R., Pedersen, K. S., Schauer, T., Staffeldt, M. M., Christensen, J. F., Højman, P., Pedersen, B. K., & Gehl, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1817550 · Cited by 33
Lü, Y., Ng, A. H. C., Chow, F. E., Everson, R. G., Helmink, B. A., Tetzlaff, M. T., Thakur, R., Wargo, J. A., Cloughesy, T. F., Prins, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24293-4 · Cited by 30
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
“Impressively, for a number of recalcitrant and otherwise uncur‐ able tumors, such as advanced melanoma (AM), metastatic melanoma (MM) or advanced non‐small cell lung cancer (NSCLC), the use of ICIs has led to a substantial long‐term remission (37,38).”
BackgroundEggermont, A. M. M., Meshcheryakov, A., Atkinson, V. G., Blank, C. U., Mandalà, M., Long, G. V., Barrow, C., Giacomo, A. M. D., Fisher, R. A., Sandhu, S. K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.023 · Cited by 34
Self-citationAdverse events induced by nivolumab and ipilimumab combination regimens
Somekawa, K., Horita, N., Kaneko, A., Tagami, Y., Fukuda, N., Matsumoto, H., Namkoong, H., Fujiwara, Y., Minegishi, K., Fukumoto, T., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211058393 · Cited by 33
Altan, M., Soto, F., Zhong, L., Akhmedzhanov, F., Wilson, N. R., Zarifa, A., Albittar, A. A., Yang, V. W., Lewis, J., Rinsurongkawong, W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad118 · Cited by 34
“12-14 In contrast to the well-characterized temporal patterns of classic chemotherapy toxicities, such as alopecia, nausea/vomiting, and myelosup-pression, the onset and duration of irAEs are unpredictable, and predisposing factors for individuals to develop irAEs remain unclear.”
BackgroundHieken, T. J., Nelson, G. D., Flotte, T. J., Grewal, E. P., Chen, J., McWilliams, R. R., Kottschade, L. A., Yang, L., Domingo‐Musibay, E., Dronca, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45798-8 · Cited by 33
Innate Immune Cells in Melanoma: Implications for Immunotherapy
Trocchia, M., Ventrici, A., Modestino, L., Cristinziano, L., Ferrara, A. L., Palestra, F., Loffredo, S., Capone, M., Madonna, G., Romanelli, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158523 · Cited by 33
“Nivolumab (NIVO) is a humanized mAb that blocks the activation of the PD-1 receptor on the surface of T and B lymphocytes [52], with a lower rate of adverse events than adjuvant ipili-mumab [53].”
BackgroundSelf-citationThe impact of effective systemic therapies on surgery for stage IV melanoma
Smith, M. J. F., Smith, H. G., Joshi, K., Gore, M. E., Strauß, D., Hayes, A. J., & Larkin, J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.008 · Cited by 29
Self-citationImmune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales
Fan, L., Li, Y., Chen, J., Zheng, Y., & Xu, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.050 · Cited by 30
Madu, M. F., Franke, V., van de Wiel, B. A., Klop, W. M. C., Jóźwiak, K., van Houdt, W. J., Wouters, M. W. J. M., & van Akkooi, A. C. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000643 · Cited by 28
Rochefoucauld, J. D. L., Noël, N., & Lambotte, O. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02295-2 · Cited by 32
Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma
Morrison, S. L., & Han, D. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00819-2 · Cited by 28
Maio, M., Blank, C. U., Necchi, A., Giacomo, A. M. D., Ibrahim, R. A., Lahn, M., Fox, B. A., Bell, R. B., Tortora, G., & Eggermont, A. M. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.035 · Cited by 30
Self-citationPD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
D’Alessio, A., Rimassa, L., Cortellini, A., & Pinato, D. J. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s284440 · Cited by 33
Bloemendal, M., Bol, K. F., Boudewijns, S., Gorris, M. A. J., de Wilt, J. H. W., Croockewit, S., van Rossum, M. M., de Goede, A. L., Petry, K., Koornstra, R. H. T., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2015113 · Cited by 34
“HRQoL of patients treated with adjuvant nivolumab or dabrafenib/trametinib remained unchanged during the trial.(33,63) However, despite the expected recovery from RLND, a non-clinically relevant decline in HRQoL during adjuvant treatment with ipilimumab and pembrolizumab was found.”
BackgroundTriplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Dixon-Douglas, J. R., Patel, R. P., Somasundram, P. M., & McArthur, G. A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01243-x · Cited by 31
Mulder, E. E. A. P., Johansson, I., Grünhagen, D. J., Tempel, D., Rentroia‐Pacheco, B., Dwarkasing, J. T., Verver, D., Mooyaart, A. L., van der Veldt, A. A. M., Wakkee, M., et al. (2022) · Cancers · doi:10.3390/cancers14122854 · Cited by 29
Neoadjuvant treatment for stage III and IV cutaneous melanoma
Gorry, C., McCullagh, L., O’Donnell, H., Barrett, S., Schmitz, S., Barry, M. G., Curtin, K., Beausang, E. S., Barry, R., & Coyne, I. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012974.pub2 · Cited by 44
A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence
Rwandamuriye, F. X., Evans, C. W., Wylie, B., Nörret, M., Vitali, B., Ho, D., Nguyen, D., Roper, E. A., Wang, T., Hepburn, M. S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101113 · Cited by 33
“In addition, the required systemic administration exposes all organ systems to these antibodies, which results in frequent and significant toxicity.(6) There is a strong clinical need for more effective and”
BackgroundContemporary Approaches to In-Transit Melanoma
Perone, J. A., Farrow, N., Tyler, D. S., & Beasley, G. M. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00063 · Cited by 30
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.